

18 MAR 2024

# German Parliamentarian Subcommittee for Global Health

Marie-Ange Saraka-Yao

Chief Resource Mobilisation and Growth Officer

**Deutscher Bundestag** 

Ausschuss für Gesundheit

Ausschussdrucksache 20(14-1)74

ΓΟΡ 2 Sitzung UA GlobG 18.03.20

18.03.2024



## Gavi has reached more than 1 billion children since 2000

The Alliance is on track to meet its 2021-2025 commitments (Gavi 5.1): vaccinating an additional 300 million children, saving more than 7 million lives and generating economic benefits of US\$80 - 100 billion.



## Looking ahead: Gavi in 6.0 can make decisive progress towards Sustainable Development Goal 3 before 2030



Extending the power of existing vaccines such as the one against human papillomavirus (HPV) so that women of all ages are protected against cervical cancer.



Introducing new powerful vaccines, including the newly approved malaria vaccine to tackle one of the biggest killer of children in Africa, and protect against climate-sensitive diseases.



Extending routine protection against polio through the Inactivated Polio Vaccine (IPV) to insure the world against polio re-emergence and increase emergency stockpile investment to support countries' responses to rising numbers of deadly disease outbreaks like Cholera, Ebola & Yellow Fever.



Reaching zero-dose children, currently unprotected, to ensure equity and drive down prices as vaccine volumes increase, even if new vaccines are initially more expensive.



Combating outbreaks, prevent and prepare for the next pandemic, and establishing a Day Zero Financing Facility with available surge capacity. Additionally, the African Vaccine Market Accelerator serves as a pioneering initiative to support sustainable local production.

#### Contextual developments need to be considered for Gavi 6.0

#### Key trends



Backsliding of RI following the COVID-19 pandemic in Gavi-supported countries, though signs of recovery in 2022.



**Increased pressures on health systems,** especially in lower-income countries (LICs), stemming from **drivers of vulnerability**: population growth, urbanisation, growing fragility & conflicts, migration.



Climate change further exacerbates the drivers of vulnerability posing an unprecedented challenge to global health, increasing the risk of poly-epidemics, AMR and disproportionately affecting LICs and the most vulnerable communities.



Innovation in immunization systems and technologies, new vaccine agenda.



Reshaping of the global health architecture, changes in the geopolitical landscape with a politicization of int. development. Donors increasingly face fiscal challenges.



#### **Gavi 6.0: The Road to Replenishment**







2025

2026

#### June 2024

## **2026-2030 Investment Opportunity Launch**

- Call to Action for Immunization and the official launch of Gavi's replenishment campaign.
- Introduction to Gavi's priorities, targets & funding asks for 2026-2030.
- Political support for the Alliance.

## African Vaccine Manufacturing Accelerator (AVMA) launch

- Official launch of AVMA a strong, collective response to the health challenges faced by Africa, in partnership between Gavi and African partners, particularly Africa CDC, the AU and African leaders.
- Presentation of AVMA targets and milestones.
- Unveiling of donor contributions to AVMA.

#### **Format of the Event**

Date: 20th of June

Co-Host: France & Africa CDC

Participants: 200 participants,

including Heads of State and Ministers

from donor and implementing

countries as well as representatives of

local and private sector partners.



## Vielen Dank






18 MAR 2024

## Annex



### A strengthened collaboration with the Global Fund



#### **Workstreams**

Malaria

Developing a model for collaboration, utilizing the full malaria toolkit, with a focus on complementary programming, communications, funding and replenishment approaches putting countries first and optimizing health outcomes.

Health
Systems
Strengthening

Increasing **in-country coordination** of our investments in health systems, service delivery, and M&E frameworks, including working with implementing partners to align on **HSS metrics**.

**Country Engagement** 

**Simplify country-facing processes** with a focus on challenging operating environments and collaborate with the Malaria workstream on how to strengthen joint country engagement around the **rollout of R21**.

**Back Office** 

Identify additional opportunities for collaboration across **business-enabling functions** within the Global Health Campus (e.g., IT, HR, admin, ops) to improve effectiveness and efficiencies.

